Analysis of activating GCM2 sequence variants in sporadic parathyroid adenomas

Aaliyah Riccardi, Tori Aspir, Lilia Shen, Chia Ling Kuo, Taylor C. Brown, Reju Korah, Timothy D. Murtha, Justin Bellizzi, Kourosh Parham, Tobias Carling, Jessica Costa-Guda, Andrew Arnold

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Context: Sporadic, solitary parathyroid adenoma is the most common cause of primary hyperparathyroidism (PHPT). Apart from germline variants in certain cyclin-dependent kinase inhibitor genes and occasionally in MEN1, CASR, or CDC73, little is known about possible genetic variants in the population that may confer increased risk for development of typical sporadic adenoma. Transcriptionally activating germline variants, especially within in the C-terminal conserved inhibitory domain (CCID) of glial cells missing 2 (GCM2), encoding a transcription factor required for parathyroid gland development, have recently been reported in association with familial and sporadic PHPT. Objective: To evaluate the potential role of specific GCM2 activating variants in sporadic parathyroid adenoma. Design and Patients: Regions encoding hyperparathyroidism-associated, activating GCM2 variants were PCR amplified and sequenced in genomic DNA from 396, otherwise unselected, cases of sporadic parathyroid adenoma. Results: Activating GCM2 CCID variants (p.V382M and p.Y394S) were identified in six of 396 adenomas (1.52%), and a hyperparathyroidism-associated GCM2 non-CCID activating variant (p.Y282D) was found in 20 adenomas (5.05%). The overall frequency of tested activating GCM2 variants in this study was 6.57%, approximately threefold greater than their frequency in the general population. Conclusions: The examined, rare CCID variants in GCM2 were enriched in our cohort of patients and appear to confer a moderately increased risk of developing sporadic solitary parathyroid adenoma compared with the general population. However, penetrance of these variants is low, suggesting that the large majority of individuals with such variants will not develop a sporadic parathyroid adenoma.

Original languageEnglish
Pages (from-to)1948-1952
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume104
Issue number6
DOIs
StatePublished - Jun 1 2019
Externally publishedYes

Fingerprint Dive into the research topics of 'Analysis of activating GCM2 sequence variants in sporadic parathyroid adenomas'. Together they form a unique fingerprint.

  • Cite this

    Riccardi, A., Aspir, T., Shen, L., Kuo, C. L., Brown, T. C., Korah, R., Murtha, T. D., Bellizzi, J., Parham, K., Carling, T., Costa-Guda, J., & Arnold, A. (2019). Analysis of activating GCM2 sequence variants in sporadic parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism, 104(6), 1948-1952. https://doi.org/10.1210/jc.2018-02517